Aeglea Bio Therapeutics (NASDAQ: AGLE) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Aeglea Bio Therapeutics to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability.

Profitability

This table compares Aeglea Bio Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aeglea Bio Therapeutics -527.99% -44.05% -41.00%
Aeglea Bio Therapeutics Competitors -5,317.76% -430.59% -39.70%

Earnings and Valuation

This table compares Aeglea Bio Therapeutics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aeglea Bio Therapeutics $4.63 million -$21.69 million -2.78
Aeglea Bio Therapeutics Competitors $284.30 million $34.29 million 131.09

Aeglea Bio Therapeutics’ rivals have higher revenue and earnings than Aeglea Bio Therapeutics. Aeglea Bio Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aeglea Bio Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aeglea Bio Therapeutics 0 0 0 0 N/A
Aeglea Bio Therapeutics Competitors 843 3192 11577 230 2.71

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.01%. Given Aeglea Bio Therapeutics’ rivals higher probable upside, analysts clearly believe Aeglea Bio Therapeutics has less favorable growth aspects than its rivals.

Risk & Volatility

Aeglea Bio Therapeutics has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500. Comparatively, Aeglea Bio Therapeutics’ rivals have a beta of 1.84, suggesting that their average stock price is 84% more volatile than the S&P 500.

Insider & Institutional Ownership

46.9% of Aeglea Bio Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 27.0% of Aeglea Bio Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aeglea Bio Therapeutics rivals beat Aeglea Bio Therapeutics on 5 of the 9 factors compared.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.